アラバマ州における乳がんの臨床試験
アラバマ州内の拠点で、乳がんに関する29件の研究が参加者を募集しています。
アラバマ州内の都市
公式研究テキスト（英語）
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- Central Alabama Research, Birmingham
被験者募集中第3相
18歳〜100歳 · 全性別 · 2026/10/02更新 · NCT05827081A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital, Birmingham
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06760819A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
- Alabama Oncology, Birmingham
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06369285PRE-ISPY Phase I/II Oncology Platform Program
- The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/30更新 · NCT05868226Phase II Single Arm Trial of Low Dose Capecitabine in Patients With Advanced Breast Cancer
- University of Alabama at Birmingham, Birmingham
被験者募集中第2相
60歳以上 · 女性 · 2026/09/30更新 · NCT06105684A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- Southern Cancer Center (SCC) ( Site 8000), Daphne
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07060807An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
- University of Alabama At Birmingham Hospital, Birmingham
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07222267A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Research Site, Daphne
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06103864Improved Successful Retrieval Rate of HydroMARK Plus Breast Biopsy Site Marker in Comparison to HydroMARK as Well as Improved Surgeon Satisfaction
- The Kirklin Clinic, Birmingham
被験者募集中
18歳〜90歳 · 女性 · 2026/09/25更新 · NCT06294574A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- University of Alabama at Birmingham, Birmingham
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/23更新 · NCT06618287A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
- University of Alabama at Birmingham, Birmingham
被験者募集中第2相
18歳以上 · 女性 · 2026/09/22更新 · NCT07287098Women Informed to Screen Depending on Measures of Risk (Wisdom Study)
- University of Alabama at Birmingham, Birmingham
被験者募集中健康なボランティア歓迎
30歳〜74歳 · 女性 · 2026/09/21更新 · NCT02620852A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- Southern Cancer Center, PC, Daphne
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/15更新 · NCT06492616Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- University of Alabama Birmingham, Birmingham
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/10更新 · NCT06293898Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
- Birmingham Hematology Associates, Birmingham
被験者募集中観察研究
18歳〜99歳 · 全性別 · 2026/09/03更新 · NCT07211178TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
- University of Alabama, Birmingham
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/26更新 · NCT06533826Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
- Southern Cancer Center, Mobile
被験者募集中第3相
18歳〜100歳 · 全性別 · 2026/08/06更新 · NCT05232916Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts
- University of Alabama, Birmingham, Birmingham
被験者募集中健康なボランティア歓迎
45歳〜74歳 · 女性 · 2026/07/31更新 · NCT05625659Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
- Uni of Alabama at Birmingham, Birmingham
被験者募集中第1相
18歳〜100歳 · 全性別 · 2026/07/29更新 · NCT06562192Promoting Resilience in Women With Breast Cancer (PRISM -MBC)
- The University of Alabama, Birmingham
被験者募集中
18歳以上 · 全性別 · 2026/05/15更新 · NCT06855654I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- University of Alabama at Birmingham, Birmingham
被験者募集中第2相
18歳以上 · 全性別 · 2026/05/06更新 · NCT01042379Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
- University of Alabama at Birmingham, Birmingham
- University of South Alabama, Mobile
被験者募集中
18歳以上 · 全性別 · 2026/04/30更新 · NCT05297734De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
- University of South Alabama Mitchell Cancer Institute, Mobile
被験者募集中第3相
50歳〜70歳 · 全性別 · 2026/04/23更新 · NCT04852887A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
- University of Alabama at Birmingham, Birmingham
被験者募集中第2相
18歳以上 · 全性別 · 2026/02/25更新 · NCT06099769Positron Emission Tomography (PET) Imaging With Zirconium-89 (89Zr)-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness
- The Kirklin Clinic, Birmingham
被験者募集中早期第1相
18歳以上 · 女性 · 2026/01/26更新 · NCT03321045Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
- University of Alabama Birmingham, Birmingham
被験者募集中第2相
18歳以上 · 全性別 · 2026/01/20更新 · NCT05693766Time-Restricted Eating and Cancer: Clinical Outcomes, Mechanisms, and Moderators
- The University of Alabama at Birmingham, Birmingham
被験者募集中
18歳以上 · 全性別 · 2025/12/16更新 · NCT04722341RAD 1802: Pilot Trial of Five Fraction Stereotactic Body Radiotherapy for Early Stage Breast Cancer Patients Eligible for Post-Operative Accelerated Partial Breast Irradiation (APBI)
- University of Alabama at Birmingham (UAB) Hazelrig-Salter Radiation Oncology Center (HSROC), Birmingham
被験者募集中
18歳〜99歳 · 全性別 · 2025/10/31更新 · NCT03643861SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Birmingham
- Massive Bio SYNERGY-AI site, Mobile
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。